Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection (Pediatrics (Evanston), 2014)
Keywords: Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacokinetics; Antibodies, Monoclonal, Humanized - therapeutic use; Antiviral Agents - administration & dosage; Antiviral Agents - pharmacokinetics; Antiviral Agents - therapeutic use; Child, Preschool; Comorbidity; Cystic Fibrosis - epidemiology; Down Syndrome - epidemiology; Gestational Age; Hospitalization - statistics & numerical data; Humans; Immunocompromised Host; Indians, North American - statistics & numerical data; Infant; Infant, Premature; Injections, Intramuscular; Neuromuscular Diseases - epidemiology; Palivizumab; Respiratory Sounds; Respiratory Syncytial Virus Infections - epidemiology; Respiratory Syncytial Virus Infections - ethnology; Respiratory Syncytial Virus Infections - prevention & control; Risk Factors; Seasons; RSV; palivizumab; congenital heart disease; chronic lung disease; respiratory syncytial virus; bronchiolitis; infants and young children